<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00008047</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068368</org_study_id>
    <secondary_id>FRE-GERCOR-D99-1</secondary_id>
    <secondary_id>EU-20021</secondary_id>
    <nct_id>NCT00008047</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus</brief_title>
  <official_title>Multicentre Phase II Study Of Concomitant Radio-Chemotherapy Associating Continuous Infusion 5-FU With Hydroxyuree Via Bone Marrow With Or Without Paclitaxel In Treatment Of Inoperable Epidermoid Carcinoma Of Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase I/II trial to study the effectiveness of combination chemotherapy&#xD;
      with or without paclitaxel combined with radiation therapy in treating patients who have&#xD;
      stage II or stage III cancer of the esophagus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of concurrent radiotherapy with fluorouracil and hydroxyurea with&#xD;
           or without paclitaxel in terms of survival without dysphagia in patients with inoperable&#xD;
           stage II or III epidermoid carcinoma of the esophagus.&#xD;
&#xD;
        -  Compare the overall survival, response rate, toxicity, and quality of life in this&#xD;
           patient population treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified&#xD;
      according to weight loss (less than 10% vs at least 10%) and inoperability criteria&#xD;
      (nonresectable vs due to anatomical terrain). Patients are randomized to one of two treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive fluorouracil IV continuously, oral hydroxyurea, and concurrent&#xD;
           radiotherapy daily on days 1-5.&#xD;
&#xD;
        -  Arm II: Patients receive fluorouracil, hydroxyurea and radiotherapy as in arm I.&#xD;
           Patients also receive paclitaxel IV on day 1.&#xD;
&#xD;
      Treatment continues every 2 weeks for 4 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients with possible resectable disease undergo surgical resection at 4-6 weeks following&#xD;
      the last course of chemoradiotherapy. Patients with continued unresectable disease receive 2&#xD;
      additional courses of chemoradiotherapy as above within 8-17 days following the last course&#xD;
      of chemoradiotherapy.&#xD;
&#xD;
      Quality of life is assessed at baseline, monthly during therapy, every 2 months for 6 months,&#xD;
      every 4 months for 1 year, and then every 6 months thereafter.&#xD;
&#xD;
      Patients are followed every 2 months for 6 months, every 4 months for 1 year, and then every&#xD;
      6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 90 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 1999</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxyurea</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage II (T2 or T3, N0, M0) or III (T3, N1, M0) epidermoid&#xD;
             carcinoma of the esophagus&#xD;
&#xD;
          -  Inoperable due to initial extension or inoperable with no extension&#xD;
&#xD;
          -  No visceral metastases&#xD;
&#xD;
          -  No extension to the tracheo-bronchial pathway&#xD;
&#xD;
               -  No tracheo-esophageal fistula&#xD;
&#xD;
               -  No broncho-esophageal fistula&#xD;
&#xD;
               -  No suspected respiratory mucosal involvement on bronchoscopy&#xD;
&#xD;
          -  No carcinoma in situ&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 80&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 120,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Lymphocyte count at least 1,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2 times normal&#xD;
&#xD;
          -  Albumin at least 3.0 g/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.4 mg/dL&#xD;
&#xD;
          -  Calcium less than 11.2 mg/dL&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No severe respiratory illness (e.g., severe broncho-pathway obstruction or&#xD;
             insufficient respiration)&#xD;
&#xD;
          -  No uncontrolled broncho-pulmonary infection&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior history of malignancy except curatively treated carcinoma in situ of&#xD;
             the colon or skin cancer&#xD;
&#xD;
          -  No contraindication to fluorouracil&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No psychiatric illness&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Total protein at least 65% of normal&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No prior endocrine therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent participation in other study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Ganem, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Jean Bernard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Amiens</city>
        <zip>80054 Cedex 1</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Vincent</name>
      <address>
        <city>Besancon</city>
        <zip>25044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint - Jean</name>
      <address>
        <city>Cagne-sur-Mer</city>
        <zip>06800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Grenoble - La Tronche</name>
      <address>
        <city>Grenoble</city>
        <zip>F-38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Andre Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMC Les Ormeaux</name>
      <address>
        <city>Le Havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Laennec</name>
      <address>
        <city>Paris</city>
        <zip>75007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ste - Marie</name>
      <address>
        <city>Pontoise</city>
        <zip>95301</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique De Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>F-51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Fleming</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2001</verification_date>
  <study_first_submitted>January 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

